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Background/purpose: Poorly crystalline hydroxyapatite was improved so that it 
has better cell affinity in vitro. We studied the efficacy of a novel resorbable poorly 
crystalline hydroxyapatite-based biphasic calcium phosphate, BonaGraft, for bone 
regeneration in vivo.
Materials and methods: The beagle was used as an animal model, and cylindrical 
artificial bone defects (3 mm in diameter and 6 mm long) were produced in the alveo-
lar bone. The BonaGraft (ratio of poorly crystalline hydroxyapatite to β-tricalcium 
phosphate, 60:40) was used to fill in the defect, and unfilled defects served as a con-
trol group. At 5, 8 and 10 weeks after the operation, the size of the residual graft and 
new bone formation were evaluation by a histomorphometric analysis. In a clinical trial, 
33 enrolled patients included 15 males and 18 females with ages ranging from 35 to 54 
years. The main indications were ridge augmentation (n = 12), sinus lifting (n = 2), 
repair of periodontal disease (n = 14), and repair of radicular cysts (n = 5). The clinical 
outcomes of the surgery were primarily evaluated by clinical radiographs.
Results: In the animal study, implanting BonaGraft produced greater new-bone for-
mation (74.5% ± 1.0%) at 10 weeks postoperatively than that of the control (40.2% ± 
0.3%). BonaGraft particles were gradually resorbed and substituted by bone. The in vivo 
graft resorption time and bone healing time of 12.1 weeks were mathematically 
determined by the least squares method. In the clinical test, all patients implanted 
with BonaGraft reported satisfactory clinical outcomes without major material-related 
side effects. According to the radiographic pictures, implantation of BonaGraft 
enhanced bone formation.
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Introduction
For several decades, typical graft materials in-
clude both transplanted bone and bioceramics for 
bone regeneration. Autotransplanted bone is the 
gold standard in clinical practice because of its 
osteoinductive and osteogenesis properties. How-
ever, autologous bone is limited in terms of avail-
ability as well as owing to secondary harm caused 
to patients.1,2 Allotransplanted bone is usually 
taken from disinfected cadaveric bones. Potential 
immune responses can be induced by antigens of 
the allograft with an associated risk of disease 
transmission, especially in cases of human immun-
odeficiency virus and hepatitis.1 To minimize donor 
site morbidity, artificial bone substitutes exhibit-
ing good biocompatibility and osteoconduction are 
widely used in orthopedic and dental fields.
Calcium phosphate is widely used as a bone graft 
substitute owing to biomimicry of similar inorganic 
components of bones and teeth. After implanting a 
bioceramic material, new bone gradually replaces 
the implant together with graft resorption; ac-
cordingly, the periods of graft absorption and bone 
regeneration should be matched to achieve the 
optimal bone regeneration efficiency. Hydroxyapa-
tite (HAp), β-tricalcium phosphate (β-TCP), and 
calcium sulfate are most widely used in the clinic 
for bone regeneration. In conventional products, 
the resorption times for HAp, β-TCP, and calcium 
sulfate are about 1−3 years, 0.5−1 year, and 1−2 
months, respectively.3 In 2006, Rack et al.4 reported 
that unabsorbed bone graft deposits may influence 
treatment of the implant bed. Knabe et al.5 con-
cluded that the resorption time for bone grafts 
used in ridge preservation contexts should be less 
than 6 months, or the grafts may hinder new bone 
formation and delay the healing process. Ordinar-
ily, bone tissue needs 3−6 months to mature under 
unloaded conditions.6 For this reason, the use of 
calcium sulfate (with a resorption time of 1−2 
months) may lead to soft-tissue invasion that sub-
sequently hinders bone regeneration. For the 
aforementioned reasons, grafts with a 3−6 month 
resorption period may be appropriate for dental 
applications.
In general, β-TCP has a median resorption pe-
riod of around 6−12 months, but its cell affinity is 
lower than that of HAp. Jalota et al.7 reported 
Conclusion: According to the animal study results, BonaGraft has a suitable resorp-
tion period and satisfactory outcomes of new bone formation. The clinical study 
produced high satisfaction with clinical results both objectively and subjectively. 
For this reason, BonaGraft seems to be an alternative choice for a bone substitute in 
dental applications.
Table 1. Composition of commercial synthetic calcium 
phosphate products
Product name
 PC-HAp  β-TCP 
 (%) (%)
Pro Osteon (Biomet, Warsaw,  100 0
 IN, USA)
Endobon (Merck, Darmstadt, 100 0
 Germany)
MBCP (Biomatlante, Vigneux 60 40
 de Bretagne, France)
Triosite (Zimmer, Warsaw, IN, USA) 60 40
BCP (Bioland, Toulouse, France) 60 40
Collagraft (Zimmer) 60 40
Ostilit (Stryker, Kalamazoo,  20 80
 MI, USA)
BoneSave (Stryker) 20 80
Vitoss (Orthovita, Malvern, 0 100
 PA, USA)
Cerasorb (Curasan, Kleinostheim, 0 100
 Germany)
PC-HAp = poorly crystalline hydroxyapatite; β-TCP = β-tricalcium 
phosphate.
that the addition of HAp into β-TCP may enhance 
cell attachment. Nery et al.8 also concluded that 
biphasic calcium phosphate (BCP) with a high HAp 
content may be desirable for repairing periodontal 
defects. For this reason, most ceramic bone grafts 
tend to be formulated with BCP. Various commer-
cial biphasic bone grafts and their compositions 
are listed in Table 1.
The absorption times of β-TCP and HAp are be-
yond those clinically advisable. Achieving an ap-
propriate balance between biologic activity and the 
duration of the degradation period is a key chal-
lenge in developing graft materials for dental ap-
plications. The preferred resorption time for dental 
bone grafts is within 3−6 months. According to the 
degradation mechanisms, bioceramics are gradually 
dissolved by body fluids. Usually, the material with 
a larger surface area or a lower crystalline degree 
tends to exhibit a more rapid dissolution rate. In 
fact, the mineral in natural bone is poorly crystal-
line HAp (PC-HAp).9 To achieve suitable degrada-
tion rates and biomimetic properties, the porous 
BonaGraft with poorly crystalline properties was 
designed. Clinical data were retrospectively analyzed 
and are presented in this article.
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Fig. 1 Procedures of the animal study: (A) opening the flap, (B) creating a defect, and (C) placing the graft.
Materials and methods
Animal study
Twelve beagles were obtained from the National 
Pingtung University of Science and Technology, 
Pingtung, Taiwan, for the animal study. In this study, 
three time points (5, 8 and 10 weeks) were used 
with four dogs at each time point. Prior to implan-
tation of the bone grafts, the first, second and third 
premolars were extracted to create an edentulous 
area, and six teeth were extracted from each dog. 
After 16 weeks, when all extraction sockets had 
healed, cylindrical osseous defects of 3 mm in diam-
eter and 6 mm depth were surgically created in the 
alveolar bone within the mandible by a trephine bur 
(with a diameter of 3 mm) under general anesthe-
sia, and two defects were created in each dog (one 
for the control and one for the implant). The im-
plant samples of BonaGraft (Biotech One, Taipei, 
Taiwan; PC-Hap:β-TCP ratio of 60:40) were then in-
stalled within the resulting defects (Fig. 1). The 
same surgical procedure was performed in the con-
trol group without inserting any material.
Histologic evaluation
Histologic specimens were collected at 5, 8 and 
10 weeks after the surgery to evaluate new bone 
formation and the resorption rate of the graft. 
Cylindrical osseous samples of 5 mm in diameter 
and 8 mm long were harvested, soaked in 10% buff-
ered formalin for fixation, and then sectioned using 
a low-speed cutter (TechCut 4; Allied High Tech 
Products, Rancho Dominguez, CA, USA). Formic acid 
(40%) with a 10% sodium citrate solution was used for 
decalcification until the specimen had become flex-
ible, and then the slide of a specimen was stained 
with hematoxylin and eosin. Histologic analyses were 
conducted using an optical microscope (Olympus 
EX51; Olympus, Tokyo, Japan) connected to a per-
sonal computer equipped with an image analysis 
system. For the histomorphometric analysis, areas 
of new bone, soft tissue and the residual graft were 
delineated by personal judgment of the histology, 
and selected areas of the images (residual graft and 
new bone) were quantified using the ImageJ analy-
sis package (National Institutes of Health, Bethesda, 
MD, USA).
The new bone formation ratio was calculated 
as follows: new bone formation (%) = (new bone 
area/total area of section) × 100.
Clinical test
The study was performed at Taipei Medical University 
Hospital, Taipei, Taiwan. The clinical study was ap-
proved by the hospital’s institutional review board 
(approval no. P960306). Patients who were pregnant, 
or had a medical history of bone infection, cancer, 
diabetes, tuberculosis, sickle cell anemia or im-
munologic deficits were excluded from the study. 
Thirty-three healthy patients were systemically en-
rolled in the study. The indications of patients are 
listed in Table 2 (ridge augmentation, sinus lifting, 
repair of periodontal disease, and repair of radicular 
Table 2. Summary of sex, diagnosis, and results of 33 patients
No. of patients Operation
 Results
  Outcome Complications
12 Ridge augmentation Good None
 2 Sinus lifting Good None
14 Repair of periodontal disease Good None
 5 Repair of radicular cyst Good None
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cysts). All bony defects and treatment sites were 
filled with granular BonaGraft with a particle size 
of 500−1000 μm. In all cases, a broad-spectrum an-
timicrobial drug was prescribed for 5−7 days after 
the operation. Clinical radiographs were obtained 
in all cases pre- and postoperatively to evaluate the 
efficacy of the implanted grafts.
Results
In vivo study (beagle model)
A model of beagles with alveolar bone defects (co-
lumnar defects with a diameter of 3 mm and a 
depth of 6 mm) was used in this study. Specimens 
(BonaGraft) were implanted in the defects and har-
vested 5, 8 and 10 weeks later. Histomorphometric 
values were quantified by an image analysis. Filled 
defects were compared with unfilled defects (con-
trols). All experimental dogs survived the experi-
mental period. Few wounds, inflammatory reactions 
or other complications were observed. Fig. 2 shows 
the histologic results at various harvesting times, 
and no immune or inflammatory response was evi-
dent at any implant site. The control group was filled 
with connective tissue, and no bone was found 5 
weeks after the operation. However, in the BonaGraft 
group, a lot of new bone had formed in the defect; 
the new bone formation ratio in the BonaGraft group 
was 49.5% ± 0.7% within 5 weeks (Table 3). Eight 
A B
D E F
C
500 μm
500 μm
500 μm
500 μm
500 μm
500 μm
STST
ST
NB
NB
NB
NB
NB
NB
NB
NB
NB
NB
Fig. 2 Histologic evaluation of the control and BonaGraft for 5, 8 and 10 weeks of implantation (hematoxylin and 
eosin, 100 ×). (A) Control (5 weeks), (B) control (8 weeks), (C) control (10 weeks), (D) BonaGraft (5 weeks), (E) BonaGraft 
(8 weeks), (F) BonaGraft (10 weeks). ST = soft tissue; NB = new bone.
Table 3. Histomorphometric values: comparison of 
the mean percentages of new bone formation by the 
control and BonaGraft*
 New bone formation (%)
Group
 5 weeks 8 weeks 10 weeks
Control ND 18.9 ± 8.6 40.2 ± 0.3
BonaGraft 49.5 ± 0.7 68.1 ± 11.7 74.5 ± 1.0
*Values reported are an average of n = 4. ND = not detected.
weeks postoperatively, some new bone had formed 
in the control group, and the new bone formation 
ratio was 18.9 ± 8.6%. The defects filled with 
BonaGraft contained a lot of regenerated bone, 
and the new bone formation was 68.1% ± 11.7%. 
Ten weeks after the operation, new bone formation 
of the control and BonaGraft had increased to 
40.2% ± 0.3% and 74.5% ± 1.0%, respectively. According 
to the above results, implanting BonaGraft in bony 
defects indeed enhanced bone regeneration. The re-
sorption rate of the graft was also evaluated by a 
histomorphometric method.10 The histo mor phometric 
results showed that the graft was gradually re-
sorbed with the implanted time, and the average par-
ticle size decreased from 750 ± 250 μm to 100 ± 75 μm 
within 10 weeks (Fig. 3). According to the histomorpho-
metric results, the resorption period of the math-
ematical prediction was 12.1 weeks.
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Fig. 3 Histomorphometric values of the particle size of residual BonaGraft in vivo after 5, 8 and 10 weeks.
A CB
Fig. 4 Surgical procedure for ridge augmentation. (A) Before operation, (B) operative site (open flap), and (C) graft 
placement and covering membrane.
Clinical study
According to the above-described results, the effi-
ciency of BonaGraft was remarkable. In the pre-
clinical study, BonaGraft was used as a bone substitute 
to enhance bone regeneration. Thirty-three pa-
tients were recruited for this study. The patients 
were enrolled because of ridge augmentation (n = 12), 
sinus lifting (n = 2), repair of periodontal disease 
(n = 14), and repair of radicular cysts (n = 5) (Table 2). 
All treatment sites were covered with collagen mem-
branes, except in the case of the patients with 
radicular cysts. All patients reported satisfactory 
outcomes, including occlusion. None of the patients 
exhibited postoperative problems besides normal 
swelling and inflammation at the surgical site as de-
termined during the follow-up clinical and radio-
graphic examinations.
In patients with ridge augmentation, the grafts 
were covered with collagen membranes following 
placement (Fig. 4C). Regenerated ridges healed un-
eventfully; no postoperative complications were re-
corded after the ridge augmentation procedure. By 
comparing the radiographs before and after surgery 
(Fig. 5), the graft could be observed postoperatively 
with radiographs (Fig. 5B). After 2 months, the ridge 
heights had significantly increased, and the graft was 
almost invisible on the radiograph (Fig. 5C). Most pa-
tients had satisfactory outcomes, and after 2 months 
of implantation, the radiopacity of the graft had de-
creased. It was difficult to distinguish between the 
new bone and graft, and this may indicate the graft 
had been resorbed and replaced by bone tissue.
In cases of sinus lifting, the grafts were directly 
filled under the sinus membranes, and the open win-
dows were covered with a collagen membrane 
(Fig. 6).Postoperatively, the stitches were taken out 
after 2 weeks. During the healing period, no flap 
dehiscence or membrane exposure was observed. 
The length of patient follow-up was 3−6 months. 
The degree of bone augmentation in each patient 
was determined by radiographs. As shown in Fig. 7B, 
substantial bone formation was observed in the 
sinus. After the operation, all patients had satisfac-
tory outcomes, but the case number was still insuf-
ficient; for this reason, more clinical cases should 
be collected in further studies. In cases due to peri-
odontal disease, no patients had radicular lesions. 
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A CB
Fig. 5 Panoramic radiographs of ridge augmentation: (A) preoperatively, (B) postoperatively (BonaGraft), and (C) 
after 2 months.
A CB
Fig. 6 Surgical procedure for sinus floor augmentation. (A) Open window, (B) BonaGraft under the sinus membrane, 
and (C) covering by a membrane.
A B
Fig. 7 Panoramic radiographs of sinus lifting: (A) preoperatively and (B) 3 months postoperatively.
After open-flap debridement, grafts were used to 
fill the bony defects, which were then covered by 
collagen membranes (Fig. 8). After the operation, little 
membrane exposure and graft loss were seen with 
clinical observations. The outcome of surgery was con-
firmed by evaluating clinical radiographs. According 
to Fig. 9B, the alveolus bone had regenerated after 
3 months. In the surgical procedure for radicular cysts, 
a full thickness flap was reflected, and a thin piece 
of cortical bone was removed to create the bony 
window. Endodontic therapy was implemented after 
curettage of the cysts. The bony defects at the le-
sion sites were filled with BonaGraft (Fig. 10). Wound 
healing was uneventful after 1 week. A postopera-
tive radiograph was obtained to evaluate the regen-
eration of bone at the lesion site. After 6 months, 
the bony defects caused by the cyst had regenerated 
(Fig. 11), and no other clinical symptoms were evi-
dent in the follow-up examinations, which confirmed 
that apical healing was uneventful. According to 
the above results, we concluded that BonaGraft 
exhibited good efficiency, and no delayed graft 
resorption hampered bone regeneration.
Discussion
In order to measure the efficiency and absorption 
times of BonaGraft, a beagle model, which is one 
of the more frequently used large animals for or-
thopedic and dental research, was used in this study, 
as its bone composition is most similar to that of 
human bone. In the animal study, the harvest times 
were 5, 8 and 10 weeks. Pearce et al.11 reported 
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Fig. 8 Surgical procedure for periodon-
tal disease. (A) Before operation, (B) 
after debridement, (C) placement of 
BonaGraft in the defect, (D) covering by 
a membrane, and (E) after operation.
A B
Fig. 9 Radiographs of periodontal disease: (A) preoperatively and (B) 3 months postoperatively.
A B
Fig. 10 Surgical procedure for radicular cysts: (A) surgical site after debridement, and (B) placement of BonaGraft in 
the defect.
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that the bone regeneration rate and metabolism in 
beagles were 1.5 times those of human bones, and 
for this reason, the durations of the animal study 
approximated 2, 3 and 6 months in humans. Results 
of the animal study imply that all grafts could help 
enhance new bone growth in defects with good 
biocompatibility and without adverse effects.
BonaGraft has interconnected pore structures; 
these may facilitate osteocyte and neovascularized 
ingrowths. Tamai et al.12 reported that abundant 
interconnected pores may promote the ingrowth 
of bone tissue, bone marrow, and blood vessels. This 
promotes bone remodeling throughout the material. 
Certain other papers reported that calcium phos-
phate with macropores and micropores may ex-
hibit intrinsic osteoinductivity. Such a geometry is 
believed to allow the entrapment and concentration 
of circulating growth factors and osteoprogenitor 
cells that may be responsible for bone forma-
tion.9,13 As to the resorption rate, the interconnected 
porous structure can enhance the surface area of 
the bone graft, and a graft with a larger surface 
area would theoretically exhibit faster dissolution 
rates under physiologic conditions.9
BonaGraft is composed of PC-HAp and β-TCP. 
Oonishi et al.14 reported that PC-HAp exhibits suit-
able resorption rates and better bioactivity in 
bone graft areas. Our histologic results also 
showed that specimens of BonaGraft had high new 
bone formation rates, as evidenced by the pres-
ence of smaller trabecular bones surrounded by 
blood vessel-like cavities.
According to the histomorphometric results and 
a linear regression, we conjectured that the resid-
ual graft should gradually be resorbed within 3 
months in canines (Figs. 2 and 3). According to the 
relationship of the canine and human metabolic 
rates, we estimated that the resorption period of 
BonaGraft may be approximately 4−5 months in 
humans. For this reason, PC-HAp added to a graft 
may be resorbed more evenly and quickly in vivo, 
and thus it may be a better bone replacement ma-
terial than fully crystallized HAp.
In light of the above-described results, we chose 
BonaGraft for the preclinical study because of its 
superior performance in an animal study. The re-
sults of the clinical study revealed a favorable solu-
bility and biocompatibility of the tested bone graft 
as evidenced by the almost complete bone regen-
eration without a foreign body reaction. During the 
surgery, the graft was mixed with blood to form a 
slurry that was easy to shape and position onto 
treatment sites. In cases of ridge augmentation, 
the patients needed bone augmentation owing to the 
lack of alveolus bone during implantation proce-
dures. As shown in Fig. 5A, the patient’s ridge was 
absorbed because of long-term hypodontia. After 
implanting BonaGraft, a lot of granular grafts were 
observed on a radiograph (Fig. 5B). Two months later, 
the ridge heights had significantly improved. From 
the radiographic picture (Fig. 5C), an image of the 
residual graft can be found in the regenerated bone 
by radiography. It seems that grafts may gradually be 
resorbed and substituted by new bone. In 2004, 
Tischler and Misch15 reported that when large facial 
walls of bone are missing (e.g., in cases of ridge 
augmentation, sinus lifting, and periodontal debri-
dement), a barrier membrane should be used to con-
tain the graft material, and this can prevent 
ingrowth of fibrous tissues. In sinus lifting applica-
tions, BonaGraft was placed under the sinus mem-
brane and covered with a collagen membrane (Fig. 
6). According to Fig. 7, the vertical bone height 
below the sinus area increased with BonaGraft 
implantation. In 2004, Yamamichi and Itose16 used a 
sandwich method to elevate the sinus floor for im-
mediate implantation. With the sandwich method, 
non-absorptive HAp was placed near the sinus 
A B
Fig. 11 Radiograph of a radicular cyst: (A) preoperatively and (B) 3 months postoperatively.
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membrane side to make a space, a mixture of 
BonaGraft and platelet-rich plasma was filled in 
the middle layer for new bone formation, and au-
togenous bone was placed around the implant to 
encourage early osseointegration. After 1 year, the 
implants had become imbedded with new bone. 
The authors mentioned that BonaGraft exhibited a 
high affinity for platelet-rich plasma; the mixture 
decreased the use of autografts and allografts in 
complicated cases of sinus lifting. In cystic bone 
lesions that are often self-healing or can be cured 
by decompression,17 filling the lesions with bone 
graft material may help stabilize blood clots in de-
fects and consequently lead to advanced bone re-
generation.18 In this study, cystic lesions were 
filled with the graft after debridement. The le-
sions had almost fully healed after 3 weeks, and no 
adverse reactions were observed. In the periodontal 
defect cases, BonaGraft also helped with alveolar 
bone regeneration. Nery et al.8 reported that BCP 
with a higher HAp content appeared to demonstrate 
improved attachment levels and bone regeneration 
when treating periodontal osseous defects. Sun 
et al.19 also reported that non-crystalline calcium 
phosphate may significantly increase the adhesion 
and proliferation of periodontal ligament cells com-
pared with bare glass slides, and suggested that non-
crystalline calcium phosphate not only initiates 
mineralization but also plays a role in the regulating 
cell physiology. According to the aforementioned 
reference, decreased crystallinity of calcium phos-
phate or an increased ratio of HAp in BCP may be 
more suitable for periodontal operations. In sum-
mary, we concluded that low-crystalline and porous 
BCP should be efficacious for bone formation in den-
tal applications. However, long-term follow-up and 
additional cases are needed to confirm our results.
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